BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 32688395)

  • 1. Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
    Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernández-Rivas JÁ; Miras F; Fernández Escalada N; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; López-Jiménez J; Naya D; Garcia-Marco JA; Skånland SS; Cordoba R; Eyre TA
    Blood; 2020 Sep; 136(10):1134-1143. PubMed ID: 32688395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
    Thibaud S; Tremblay D; Bhalla S; Zimmerman B; Sigel K; Gabrilove J
    Br J Haematol; 2020 Jul; 190(2):e73-e76. PubMed ID: 32433778
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report.
    Cuneo A; Scarfò L; Reda G; Varettoni M; Quaglia FM; Marchetti M; De Paoli L; Re F; Pietrasanta D; Rigolin GM; Orsucci L; Ibatici A; Gattei V; Mauro FR; Trentin L; Laurenti L; Marasca R; Foà R
    Blood; 2020 Aug; 136(6):763-766. PubMed ID: 32559271
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
    Scarfò L; Chatzikonstantinou T; Rigolin GM; Quaresmini G; Motta M; Vitale C; Garcia-Marco JA; Hernández-Rivas JÁ; Mirás F; Baile M; Marquet J; Niemann CU; Reda G; Munir T; Gimeno E; Marchetti M; Quaglia FM; Varettoni M; Delgado J; Iyengar S; Janssens A; Marasca R; Ferrari A; Cuéllar-García C; Itchaki G; Špaček M; De Paoli L; Laurenti L; Levin MD; Lista E; Mauro FR; Šimkovič M; Van Der Spek E; Vandenberghe E; Trentin L; Wasik-Szczepanek E; Ruchlemer R; Bron D; De Paolis MR; Del Poeta G; Farina L; Foglietta M; Gentile M; Herishanu Y; Herold T; Jaksic O; Kater AP; Kersting S; Malerba L; Orsucci L; Popov VM; Sportoletti P; Yassin M; Pocali B; Barna G; Chiarenza A; Dos Santos G; Nikitin E; Andres M; Dimou M; Doubek M; Enrico A; Hakobyan Y; Kalashnikova O; Ortiz Pareja M; Papaioannou M; Rossi D; Shah N; Shrestha A; Stanca O; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Coscia M; Stamatopoulos K; Rossi G; Rambaldi A; Montserrat E; Foà R; Cuneo A; Ghia P
    Leukemia; 2020 Sep; 34(9):2354-2363. PubMed ID: 32647324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
    Pleyer C; Ali MA; Cohen JI; Tian X; Soto S; Ahn IE; Gaglione EM; Nierman P; Marti GE; Hesdorffer C; Lotter J; Superata J; Wiestner A; Sun C
    Blood; 2021 Jan; 137(2):185-189. PubMed ID: 33259596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic.
    Sehn LH; Kuruvilla P; Christofides A; Stakiw J
    Curr Oncol; 2020 Jun; 27(3):e332-e335. PubMed ID: 32669941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.
    Langerbeins P; Eichhorst B
    Acta Haematol; 2021; 144(5):508-518. PubMed ID: 33631756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
    Baumann T; Delgado J; Montserrat E
    Leukemia; 2020 Jul; 34(7):1954-1956. PubMed ID: 32433507
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
    Šimkovič M; Turcsányi P; Špaček M; Mihályová J; Ryznerová P; Maco M; Vodárek P; Écsiová D; Poul H; Móciková H; Zuchnická J; Panovská A; Lekaa M; Oršulová M; Prchlíková A; Stejskal L; Mašlejová S; Brychtová Y; Bezděková L; Papajík T; Lysák D; Trněný M; Smolej L; Doubek M
    Ann Hematol; 2023 Apr; 102(4):811-817. PubMed ID: 36847805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.
    Tremblay D; Seah C; Schneider T; Bhalla S; Feld J; Naymagon L; Wang B; Patel V; Jun T; Jandl T; Rahman F; Liu STH; Aberg JA; Bouvier N;
    Cancer Med; 2020 Nov; 9(22):8571-8578. PubMed ID: 32945149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
    Barrasa H; Rello J; Tejada S; Martín A; Balziskueta G; Vinuesa C; Fernández-Miret B; Villagra A; Vallejo A; San Sebastián A; Cabañes S; Iribarren S; Fonseca F; Maynar J;
    Anaesth Crit Care Pain Med; 2020 Oct; 39(5):553-561. PubMed ID: 32278670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.
    Ryan CE; Cheng MP; Issa NC; Brown JR; Davids MS
    Blood Adv; 2020 Apr; 4(7):1458-1463. PubMed ID: 32282880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
    Li L; Zhang W; Hu Y; Tong X; Zheng S; Yang J; Kong Y; Ren L; Wei Q; Mei H; Hu C; Tao C; Yang R; Wang J; Yu Y; Guo Y; Wu X; Xu Z; Zeng L; Xiong N; Chen L; Wang J; Man N; Liu Y; Xu H; Deng E; Zhang X; Li C; Wang C; Su S; Zhang L; Wang J; Wu Y; Liu Z
    JAMA; 2020 Aug; 324(5):460-470. PubMed ID: 32492084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
    Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
    JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study.
    Ferrando C; Mellado-Artigas R; Gea A; Arruti E; Aldecoa C; Bordell A; Adalia R; Zattera L; Ramasco F; Monedero P; Maseda E; Martínez A; Tamayo G; Mercadal J; Muñoz G; Jacas A; Ángeles G; Castro P; Hernández-Tejero M; Fernandez J; Gómez-Rojo M; Candela Á; Ripollés J; Nieto A; Bassas E; Deiros C; Margarit A; Redondo FJ; Martín A; García N; Casas P; Morcillo C; Hernández-Sanz ML;
    Rev Esp Anestesiol Reanim (Engl Ed); 2020 Oct; 67(8):425-437. PubMed ID: 32800622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.